Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Telomir Pharmaceuticals, Inc. (TELO : NSDQ)

• Company Description    Telomir Pharmaceuticals Inc. is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. Telomir Pharmaceuticals Inc. is based in BALTIMORE. Number of Employees: 6

• Price / Volume Information    Yesterday's Closing Price: $1.17 Daily Weekly Monthly 20 Day Moving Average: 375,649 shares Shares Outstanding: 29.76 (millions) Market Capitalization: $34.82 (millions) Beta: -0.90 52 Week High: $8.40 52 Week Low: $1.13 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -41.50% -43.69% 12 Week -52.82% -60.32% Year To Date -71.60% -73.40%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 100 SE 2ND STREET SUITE 2000 -1009 - MIAMI,FL 33131 USA ph: 786-396-6723 fax: - info@telomirpharma.com http://www.telomirpharma.com

• General Corporate Information    Officers Erez Aminov - Chief Executive Officer and Chairman Michelle Yanez - Chief Financial Officer Craig Eagle - Director Ned MacPherson. - Director Matthew Pratt Whalen - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 87975F104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/12/25 Share - Related Items Shares Outstanding: 29.76 Most Recent Split Date: (:1) Beta: -0.90 Market Capitalization: $34.82 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.08 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.31 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 69.57% vs. Previous Quarter: 30.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -2,009.40 12/31/24 - -1,170.58 ROA 06/30/25 - - 03/31/25 - -1,009.72 12/31/24 - -832.67 Current Ratio 06/30/25 - - 03/31/25 - 0.75 12/31/24 - 1.94 Quick Ratio 06/30/25 - - 03/31/25 - 0.75 12/31/24 - 1.94 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - -0.01 12/31/24 - 0.02 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - 0.00

Powered by Zacks Investment Research ©